BGP-15 (66611-37-8) is a cellular protectant operating by several mechanisms. It is an insulin sensitizer¹, HSP72 activator², PARP inhibitor and ROS and lipid peroxidation reducer³. It protects mitochondria in acetaminophen-induced liver injury⁴ as well as LPS-induced destabilization⁵ and activates mitochondrial fusion⁶. Displays protective effects in heart failure⁷ and traumatic brain injury⁸ in animal models.

References/Citation:

1. Peto et al. (2020), Pharmacological Overview of the BGP-15 Chemical Agent as a New Drug Candidate for the Treatment of Symptoms of Metabolic Syndrome; Molecules 25 429
2. Henstridge et al. (2014), Activating HSP72 in rodent skeletal muscle increases mitochondrial number and oxidative capacity and decreases insulin resistance; Diabetes 63 1881
3. Szabados et al. (2000), BGP-15, a nicotinic amidoxime derivative protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase; Biochem. Pharmacol. 59 937
4. Sarnyai et al. (2020), BGP-15 Protects Mitochondria in Acute Acetaminophen Overdose Induced Liver Injury; Pathol. Oncol. Res. 26 1797
5. Sumegi et al. (2017), BGP-15 Protects against Oxidative Stress- or Lipopolysaccharide-Induced Mitochondrial Destabilization and Reduces Mitochondrial Production of Reactive Oxygen Species; PLos One 12 e0169372
6. Szabo et al. (2018), Activation of mitochondrial fusion provides a new treatment for mitochondria-related diseases; Biochem. Pharmacol. 150 86
7. Sapra et al. (2014), The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice; Nat. Commun. 5 5705
8. Eroglu et al. (2014), Therapeutic inducers of the HSP70/HSP110 protect mice against traumatic brain injury; J. Neurochem. 130 626